Recently, hyperactivated insulin-like growth factor1 receptor (IGF1R) signaling was described as a possible mechanism of PI3Kδ inhibitor resistant CLL cells, suggesting IGF1R-targeted treatment as an effective strategy to overcome PI3Kδ inhibitor resistance (118, 119). Here, IGF1R is linked to B-cell chronic lymphocytic leukemia.